Kynam Capital Management, LP Xenon Pharmaceuticals Inc. Transaction History

Kynam Capital Management, LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$33.46 - $40.35 $6,390 - $7,706	-191 Reduced 0.66%	28,696 $1.03 Million
Q4 2022 Feb 14, 2023	BUY	$33.06 - $39.43 $3,140 - $3,745	95 Added 0.33%	28,887 $1.14 Million
Q3 2022 Nov 14, 2022	SELL	$30.79 - $39.82 $4.5 Million - $5.82 Million	-146,208 Reduced 83.55%	28,792 $1.04 Million
Q2 2022 Aug 15, 2022	SELL	$25.44 - $35.16 $7.84 Million - $10.8 Million	-308,270 Reduced 63.79%	175,000 $5.32 Million
Q1 2022 May 13, 2022	SELL	$25.09 - $33.13 $4.69 Million - $6.19 Million	-186,823 Reduced 27.88%	483,270 $14.8 Million
Q4 2021 Feb 14, 2022	BUY	$15.6 - $35.4 $10.5 Million - $23.7 Million	670,093 New	670,093 $20.9 Million

212

70.2M

88.3K

28.8K

Ticker XENE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,263,500
Market Cap $2.39B
Description
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopath...

Get notified when there are updates to the investment portfolio of Kynam Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Kynam Capital Management, LP with notifications on news.